a 2023

Transcriptomic analysis of esophageal tissues and potential biomarkers for differential diagnostics of Barrett´s mucosa and esophageal adenocarcinoma

BOŘILOVÁ LINHARTOVÁ, Petra, Natálie MLČŮCHOVÁ, Jan BÖHM, Petra BRENEROVÁ, Vojtěch BARTOŇ et. al.

Basic information

Original name

Transcriptomic analysis of esophageal tissues and potential biomarkers for differential diagnostics of Barrett´s mucosa and esophageal adenocarcinoma

Authors

BOŘILOVÁ LINHARTOVÁ, Petra (203 Czech Republic, guarantor, belonging to the institution), Natálie MLČŮCHOVÁ (203 Czech Republic), Jan BÖHM (203 Czech Republic), Petra BRENEROVÁ (203 Czech Republic), Vojtěch BARTOŇ (203 Czech Republic), Adam MAJER (203 Czech Republic), Zdeněk PAVLOVSKÝ (203 Czech Republic), Lumír KUNOVSKÝ (203 Czech Republic), Radek KROUPA (203 Czech Republic), Jiří DOLINA (203 Czech Republic), Ondřej URBAN (203 Czech Republic), Vít NAVRÁTIL, Tomáš HARUŠTIAK, Robert LISCHKE (203 Czech Republic), Tomáš GROLICH (203 Czech Republic), Vladimír PROCHÁZKA (203 Czech Republic), Lydie IZAKOVIČOVÁ HOLLÁ (203 Czech Republic), Martina ZAPLETALOVÁ (203 Czech Republic), Jan LOCHMAN (203 Czech Republic), Ondřej SLABÝ (203 Czech Republic), Eva BUDINSKÁ (703 Slovakia) and Zdeněk KALA (203 Czech Republic)

Edition

Cancer Science, 2023, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Japan

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14310/23:00133535

Organization unit

Faculty of Science

Keywords in English

Barrett´s esophagus; esophageal adenocarcinoma; CDX2; MUC2; biomarkers; RNAseq
Změněno: 15/2/2024 10:20, Mgr. Terezie Slámová

Abstract

V originále

Barrett’s esophagus (BE) is considered a precancerous condition increasing the risk of esophageal adenocarcinoma (EAC) development. This study aimed to find biomarkers with the potential for differential diagnostics of BE and EAC. This pilot study comprised 24 endoscopically examined subjects, namely 12 patients with BE and 12 with EAC. Paired esophageal tissue samples (with the main pathology and adjacent tissue, paraffin-embedded) were histopathologically examined and the presence of CDX2, a diagnostic biomarker for BE//EAC, was immunohistochemically determined using a specific antibody. RNA was isolated from the paired fresh-frozen esophageal tissues, RNAseq library was prepared, and a single-read RNAseq (1x75) was conducted using an Illumina NovaSeq 6000 System. After rRNA removal and mapping to human reference, we obtained 2x 27.5-184 mil. reads per sample. Compared to EAC tissues, we observed a downregulation of the hallmark pathway for angiogenesis and an upregulated hallmark pathway for bile acid metabolism in BE (p<0.01). CDX2 protein and CDX2 gene were highly expressed in tissues with the main pathology in comparison to the adjacent tissue from both BE and EAC patients (p<0.001). On the other hand, the expression of MUC2 (mucin 2) as well as ACER2 (alkaline ceramidase 2) were upregulated in the BE tissue, and among others, TFPI2 (tissue factor pathway inhibitor 2) was downregulated in BE vs EAC tissues (p<0.001). In line with the literature, we confirmed that MUC2 is expressed in BE but not in EAC tissues. It has, therefore, the potential to serve as a biomarker of both differential diagnosis and/or prognosis.

Links

LM2023069, research and development project
Name: Výzkumná infrastruktura RECETOX
Investor: Ministry of Education, Youth and Sports of the CR, RECETOX research infrastructure
NU20-03-00126, research and development project
Name: Hostitelský mikrobiom ve vztahu k rozvoji Barrettova jícnu a adenokarcinomu jícnu
Investor: Ministry of Health of the CR, Host microbiome in relation to Barrett ́s esophagus and esophageal adenocarcinoma development, Subprogram 1 - standard